About Fortress Biotech, Inc. - Common Stock (FBIO)
Fortress Biotech Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies and technologies to address unmet medical needs. The company collaborates with various partners to identify and advance novel drug candidates across multiple therapeutic areas, including oncology, dermatology, and rare diseases. By leveraging its diverse portfolio of subsidiaries and strategic collaborations, Fortress aims to bring new treatments to the market and improve patient outcomes. Their approach combines cutting-edge research with robust clinical development strategies to enhance the effectiveness and accessibility of their therapies. Read More
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Fortress Biotech (NASDAQ: FBIO) saw its stock plunge over 30% on October 1, 2025, following the U.S. Food and Drug Administration's (FDA) issuance of a Complete Response Letter (CRL) for its New Drug Application (NDA) for CUTX-101. This investigational treatment, developed for pediatric patients suffering from the rare genetic
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.
Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.
